the Safety and Efficacy of SENL103 Autologous T Cell Injection

Conditions: Multiple Myeloma Interventions: Biological: SENL103 Sponsors: Hebei Senlang Biotechnology Inc., Ltd. Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials